Marina Biotech Announces Worldwide Exclusive Licensing Agreement With Monsanto
News Jul 02, 2012
Marina Biotech, Inc. has announced that it has entered into an exclusive licensing agreement with Monsanto Company for Marina Biotech's delivery and chemistry technologies. Terms of the agreement were not disclosed.
"We are pleased to enter into this agreement with Monsanto, a global leader in agriculture and crop sciences," stated J. Michael French, President and Chief Executive Officer of Marina Biotech.
French continued, "Over the last several years, we have been focused on bringing together novel chemistry and delivery technologies necessary to broadly apply our discovery platform across the life sciences sector. We view this license as yet another important validation of this platform and we look forward to a strong and growing relationship with Monsanto."
Sphere Fluidics and Geneva Biotech Receive Eurostars Genome Editing GrantNews
€1.6 million grant will support ‘precise docking of very large DNA cargoes in genomes’ project.READ MORE
RNAi-based Drug Shows Promise as Treatment for Chronic Hepatitis BNews
The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections.READ MORE
A More Effective Alternative to RNAi, CRISPR for Studying Protein FunctionNews
Trim-Away is a novel method enabling researchers to directly and rapidly destroy any protein in any kind of cell.READ MORE